AXIM Biotechnologies, Inc. has entered into a strategic alliance with Medical Marijuana, Inc. to research and develop applications for AXIM's patent covering water-soluble cannabinoids. The collaboration centers on AXIM's U.S. Patent No. 11,542,226 B2, titled "Polyfunctional Cannabinoids," which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body.
Under the agreement, AXIM assigned to MJNA a fifty percent right, title, and economic interest in the patent and all associated intellectual property. This includes rights to existing and future U.S. and foreign patents and applications, licensing, enforcement, and monetization proceeds, and claims for past infringement and accrued royalties. Concurrently, the companies entered into a Consulting Agreement where AXIM will provide MJNA with research and development services focused on developing applications for the patent technology. MJNA paid $600,000 to AXIM for the patent interest through a secured promissory note, and the consulting agreement includes a monthly services fee of $62,500 paid to AXIM by MJNA.
Catalina Valencia, AXIM President, stated that the alliance presents both companies with the ability to accelerate uses of the patent technology. "The water solubility of CBD and other cannabinoids is a significant development for the improved administration and increased potency of cannabinoids," Valencia said. "We believe that the patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures."
Dr. Scott, MJNA Chairman and President, expressed confidence in AXIM's team to provide R&D support for commercializing the patent technology. "The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA," Dr. Scott said. "MJNA already has significant knowledge and exposure to the cannabinoid market and enjoys relationships in that arena. We think that this alliance is a great fit, with tremendous opportunity for both MJNA and AXIM."
The patent technology offers several key advantages according to the companies. Through patented molecular engineering, novel molecules link cannabinoids to complementary compounds, substantially improving delivery mechanisms and therapeutic effectiveness. The engineered polyfunctional cannabinoids are more than 300 times more water-soluble than natural cannabinoids, enabling significantly improved absorption and therapeutic delivery. These constructs are engineered to produce more potent responses and efficacy than individual cannabinoid molecules, potentially allowing for lower therapeutic doses thereby avoiding toxic side effects associated with higher concentrations. The technology offers treatment potential for conditions where traditional lipophilic cannabinoids have demonstrated limited bioavailability, including development of sublingual applications for anxiety and other indications.
The consulting agreement has an initial, non-cancellable term of one year expiring in January 2027 and continues month-to-month thereafter until terminated by either party with 90-day written notice. For more information about AXIM Biotechnologies, visit https://www.aximbiotech.com. The strategic alliance represents a significant development in cannabinoid research, potentially expanding treatment applications and improving patient outcomes through enhanced bioavailability and administration methods.
